William Blair Downgrades Moderna to Market Perform
William Blair analyst Myles Minter downgrades Moderna (NASDAQ:MRNA) from Outperform to Market Perform.
Share
Why It Matters
An analyst thinks Moderna stock will do about as well as the rest of the market. This means the expert used to think it would do better than average.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.